Enanta Pharmaceuticals, Inc.
10.63+0.16 (+1.53%)
Oct 29, 4:00:02 PM EDT · NasdaqGS · ENTA · USD
Key Stats
Market Cap
306.71MP/E (TTM)
-Basic EPS (TTM)
-4.32Dividend Yield
0%Recent Filings
8-K
Positive zelicapavir Phase 2b results
Enanta Pharmaceuticals announced positive topline results from its Phase 2b RSVHR study of zelicapavir in 186 high-risk adults on September 29, 2025, showing statistically significant 2-day faster symptom resolution by PGI-S and up to 7.2-day faster complete resolution of all RSV symptoms in the HR3 population versus placebo. Zelicapavir also reduced hospitalization rates to 1.7% from 5.0%, achieved a 0.7 log greater viral load decline by day 5, and cleared virus in 23.9% of patients by treatment end. It proved well-tolerated. Data support Phase 3 advancement, yet risks persist in larger trials.
8-K
Positive zelicapavir Phase 2b results
Enanta Pharmaceuticals unveiled positive topline results from its Phase 2b RSVHR study of zelicapavir on September 29, 2025, showing a 6.7-day faster complete resolution of all 13 RSV symptoms in high-risk adults with CHF, COPD, or age over 75, versus placebo. The drug slashed hospitalization rates to 1.7% from 5%, while accelerating undetectable viral load by 4-5 days. Zelicapavir proved safe, with mild adverse events mirroring placebo. This bolsters Phase 3 designs, yet development risks loom large.
8-K
Interim finance leadership appointed
Enanta Pharmaceuticals appointed Harry R. Trout III as interim principal financial officer and Kathleen S. Capps as interim principal accounting officer on August 26, 2025, while CFO Paul J. Mellett takes medical leave. Both executives bring deep internal experience—Trout since 2002 in finance roles, Capps since 2016 in accounting. No new compensation arrangements were disclosed. This temporary shift ensures continuity in financial oversight amid the absence.
8-K
Enanta sues Pfizer over Paxlovid patent
Enanta Pharmaceuticals filed a patent infringement suit against Pfizer in the EU's Unified Patent Court on August 20, 2025, targeting the manufacture, use, and sale of Paxlovid in 18 participating countries under European Patent No. EP 4 051 265. This mirrors ongoing U.S. litigation over the counterpart patent. A hearing targets within 12 months. Litigation risks could distract management and pressure stock.
10-Q
Q3 FY2025 results
Enanta Pharmaceuticals posted Q3 FY2025 royalty revenue of $18.3M, edging up 2% y/y from $18.0M while dipping 13% q/q (derived), buoyed by steady MAVYRET/MAVIRET sales yet pressured by maturing HCV demand. Operating expenses fell 12% y/y to $37.2M, trimming the operating loss to $18.9M from $24.2M, with R&D down 5% to $27.2M amid focused virology and immunology efforts; net loss narrowed to $18.3M or $0.85 per share on 21.4M diluted shares, versus $22.7M or $1.07 last year. YTD revenue slid 5% y/y to $50.2M, but operating loss halved to $67.0M as costs dropped 19% to $117.2M, yielding a $63.2M net loss or $2.96 per share. Cash and equivalents stood at $44.8M with $159.3M in short-term securities for $204.1M total liquidity, while operating cash burn eased to $12.8M YTD versus $68.4M; free cash flow not disclosed in the 10-Q. Royalty liability to OMERS hit $147.7M after $18.1M payments. Patent disputes linger over Pfizer's Paxlovid.
ARMP
Armata Pharmaceuticals, Inc.
5.46+0.47
ASMB
Assembly Biosciences, Inc.
30.99+0.10
AVIR
Atea Pharmaceuticals, Inc.
3.29+0.08
COCP
Cocrystal Pharma, Inc.
1.07-0.08
HEPA
Hepion Pharmaceuticals, Inc.
0.07+0.01
HOOK
HOOKIPA Pharma Inc.
0.90+0.03
INO
Inovio Pharmaceuticals, Inc.
2.43-0.15
NNVC
NanoViricides, Inc.
1.86+0.33
TRDA
Entrada Therapeutics, Inc.
6.89-0.46
VIR
Vir Biotechnology, Inc.
5.91-0.52